Nuklearmedizin 2025; 64(01): 43
DOI: 10.1055/s-0045-1804278
Abstracts │ NuklearMedizin 2025
Leuchtturm-Vorträge
Junge Talente

Potential of MTV-based risk scores in relapsed and refractory large B-cell lymphoma: Data from a multicenter cohort undergoing chimeric antigen receptor T-cell therapy

C A Voltin
1   Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
S Flossdorf
2   Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
,
L Kurch
3   Department of Nuclear Medicine, University Hospital Leipzig, University of Leipzig, Leipzig, Deutschland
,
A Paccagnella
4   Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italien
,
M Winkelmann
5   Department of Radiology, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Deutschland
,
L Beckmann
6   Department of Internal Medicine I, Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
J M Heger
6   Department of Internal Medicine I, Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
B Casadei
4   Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italien
7   'L. e A. Seràgnoli' Institute of Hematology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria di Bologna', University of Bologna, Bologna, Italien
,
K Herrmann
8   Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
,
F J Dekorsy
9   Department of Nuclear Medicine, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Deutschland
,
N Kutsch
6   Department of Internal Medicine I, Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
P Borchmann
6   Department of Internal Medicine I, Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
S Fanti
4   Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italien
10   Division of Nuclear Medicine, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria di Bologna', University of Bologna, Bologna, Italien
,
K Rahbar
11   Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, Deutschland
,
M Subklewe
12   Department of Medicine III, Comprehensive Cancer Center Munich (CCCM), University Hospital Munich, Ludwig Maximilian University Munich, Munich, Deutschland
13   Laboratory for Translational Cancer Immunology, Gene Center Munich, Ludwig Maximilian University Munich, Munich, Deutschland
,
P L Zinzani
4   Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italien
7   'L. e A. Seràgnoli' Institute of Hematology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria di Bologna', University of Bologna, Bologna, Italien
,
A Drzezga
1   Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
M Dietlein
1   Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
C Reinhardt
14   Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
,
W G Kunz
5   Department of Radiology, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Deutschland
,
B von Tresckow
14   Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
,
R Seifert
8   Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
11   Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, Deutschland
,
J C Albring
15   Department of Medicine A – Hematology, Oncology, and Pneumology, West German Cancer Center (WTZ) Network Partner Site, University Hospital Münster, University of Münster, Münster, Deutschland
,
V Blumenberg
12   Department of Medicine III, Comprehensive Cancer Center Munich (CCCM), University Hospital Munich, Ludwig Maximilian University Munich, Munich, Deutschland
13   Laboratory for Translational Cancer Immunology, Gene Center Munich, Ludwig Maximilian University Munich, Munich, Deutschland
,
A Farolfi
10   Division of Nuclear Medicine, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria di Bologna', University of Bologna, Bologna, Italien
,
P Gödel
6   Department of Internal Medicine I, Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Deutschland
,
V Vucinic
16   Department of Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases, University Hospital Leipzig, University of Leipzig, Leipzig, Deutschland
,
C Hanoun
14   Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 

Ziel/Aim: Chimeric antigen receptor (CAR) T-cell therapy has proven highly effective in relapsed and refractory large B-cell lymphomas. Yet, it remains an open question how to identify potential non-responders ahead of treatment and further improve their outcome. Several international research groups are currently working on the integration of metabolic tumor volume (MTV), measured by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (PET), into newly developed models. Therefore, we examined the predictive value of proposed risk scores in patients undergoing CAR T-cell therapy.

Methodik/Methods: Our analysis set included 94 patients from five German university hospitals and one Italian center who underwent PET imaging before CAR T-cell treatment. We evaluated the risk scores introduced by Leithner et al. [1], Thieblemont et al. [2], and our group [3], which, alongside MTV, included lactate dehydrogenase levels, Eastern Cooperative Oncology Group performance status, and extra-nodal involvement, respectively. The performance of MTV-based models in predicting six-month progression-free survival (PFS) was determined based on receiver operating characteristic analysis and compared with the established International Prognostic Index (IPI).

Ergebnisse/Results: The risk scores considered showed different predictive power regarding PFS in patients who underwent CAR T-cell therapy. We calculated areas under the curve (AUC) of 0.53 (95% confidence interval [CI], [0.42, 0.64]), 0.62 (95% CI, [0.51, 0.72]), and 0.69 (95% CI, [0.58, 0.79]) for the models published by Leithner et al., Thieblemont et al., and our group, respectively. Moreover, the IPI, currently used within clinical routine, achieved an AUC of 0.63 (95% CI, [0.53, 0.73]).

Schlussfolgerungen/Conclusions: Our data indicate that the MTV-based models proposed may be useful for risk assessment in large B-cell lymphoma patients undergoing CAR T-cell therapy. Additionally, we demonstrated their potential to outperform the established IPI, suggesting future research should focus on PET biomarkers. A larger number of patients is currently being enrolled for an ongoing validation study.



Publikationsverlauf

Artikel online veröffentlicht:
12. März 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany